 Co-Diagnostics NASDAQ:CODX Inc announced that it has completed the acquisition of Idaho Molecular Inc and Advanced Conception Inc to provide the company with all existing and future assets and intellectual property related to its upcoming at-homepoint-of-care diagnostic device. The transaction was settled for 4.72 million shares of Co-Diagnostics NASDAQ:CODX stock, and additional common warrants totaling 465,000. 